Phil Ferneau, MBA, JD directs Borealis Ventures’ healthcare investing, leveraging 20 years of experience working with early-stage entrepreneurs to commercialize innovation. He currently leads Borealis’ investments in Adimab, Avedro, Avitide, Compass Therapeutics, and Vets First Choice. Phil was also responsible for the firm’s prior investments in GlycoFi (acquired by Merck & Co.) and M2S (acquired by AIG Altaris Health Partners). He previously served as the founding executive director of the Center for Private Equity and Entrepreneurship at Dartmouth College’s Tuck School of Business. Phil remains an adjunct member of Tuck’s faculty teaching venture capital and entrepreneurship topics. Earlier in private legal practice, he consulted technology startups, Fortune 500 companies, and foreign governments on sensitive trade, tax, and investment matters.
Phil received an AB degree from Dartmouth College, a JD from the University of Virginia School of Law, and an MBA (with High Distinction) from the Tuck School of Business at Dartmouth.